|
|
||||||||
2-Agonist fenoterol has greater effects on
contractile function of rat skeletal muscles than
clenbuterol
1 Department of Physiology, The University of Melbourne, Melbourne, Victoria 3010; and 2 School of Agriculture, Charles Sturt University, Wagga Wagga, New South Wales 2678, Australia
Potential treatments for skeletal muscle
wasting and weakness ideally possess both anabolic and ergogenic
properties. Although the
2-adrenoceptor agonist
clenbuterol has well-characterized effects on skeletal muscle, less is
known about the therapeutic potential of the related
2-adrenoceptor agonist fenoterol. We administered an
equimolar dose of either clenbuterol or fenoterol to rats for 4 wk to
compare their effects on skeletal muscle and tested the hypothesis that
fenoterol would produce more powerful anabolic and ergogenic effects.
Clenbuterol treatment increased fiber cross-sectional area (CSA) by 6%
and maximal isometric force (Po) by 20% in extensor
digitorum longus (EDL) muscles, whereas fiber CSA in soleus muscles
decreased by 3% and Po was unchanged, compared with
untreated controls. In the EDL muscles, fenoterol treatment increased
fiber CSA by 20% and increased Po by 12% above values
achieved after clenbuterol treatment. Soleus muscles of fenoterol-treated rats exhibited a 13% increase in fiber CSA and a
17% increase in Po above that of clenbuterol-treated rats.
These data indicate that fenoterol has greater effects on the
functional properties of rat skeletal muscles than clenbuterol.
-adrenoceptor; fiber type; skeletal muscle; hypertrophy; muscle
wasting; plasticity; muscle contraction
This article has been cited by other articles:
![]() |
S. M. Turpin, J. G. Ryall, R. Southgate, I. Darby, A. L. Hevener, M. A. Febbraio, B. E. Kemp, G. S. Lynch, and M. J. Watt Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice J. Physiol., April 1, 2009; 587(7): 1593 - 1605. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ryall, J. D. Schertzer, T. M. Alabakis, S. M. Gehrig, D. R. Plant, and G. S. Lynch Intramuscular {beta}2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury J Appl Physiol, July 1, 2008; 105(1): 165 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Beitzel, M. N. Sillence, and G. S. Lynch beta-Adrenoceptor signaling in regenerating skeletal muscle after beta-agonist administration Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E932 - E940. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ryall, J. D. Schertzer, and G. S. Lynch Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 813 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. O. Kline, F. J. Panaro, H. Yang, and S. C. Bodine Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol J Appl Physiol, February 1, 2007; 102(2): 740 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Burniston, L.-B. Tan, and D. F. Goldspink Relative myotoxic and haemodynamic effects of the {beta}-agonists fenoterol and clenbuterol measured in conscious unrestrained rats Exp Physiol, November 1, 2006; 91(6): 1041 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Axell, H. E. MacLean, D. R. Plant, L. J. Harcourt, J. A. Davis, M. Jimenez, D. J. Handelsman, G. S. Lynch, and J. D. Zajac Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E506 - E516. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gregorevic, J. G. Ryall, D. R. Plant, M. N. Sillence, and G. S. Lynch Chronic {beta}-agonist administration affects cardiac function of adult but not old rats, independent of {beta}-adrenoceptor density Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H344 - H349. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Busquets, M. T. Figueras, G. Fuster, V. Almendro, R. Moore-Carrasco, E. Ametller, J. M. Argiles, and F. J. Lopez-Soriano Anticachectic Effects of Formoterol: A Drug for Potential Treatment of Muscle Wasting Cancer Res., September 15, 2004; 64(18): 6725 - 6731. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Beitzel, P. Gregorevic, J. G. Ryall, D. R. Plant, M. N. Sillence, and G. S. Lynch {beta}2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury J Appl Physiol, April 1, 2004; 96(4): 1385 - 1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ryall, D. R. Plant, P. Gregorevic, M. N. Sillence, and G. S. Lynch {beta}2-Agonist administration reverses muscle wasting and improves muscle function in aged rats J. Physiol., February 15, 2004; 555(1): 175 - 188. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |